Skip to content

Regeneron increases market reach for Eylea drug following expansion of labelling by European Medicines Agency

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced that EYLEA (aflibercept) injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to macular edema, secondary to Central Retinal Vein Occlusion (CRVO). The final decision of the European Commission is expected in the second half of 2013. The drug, previously referred to as VEGF Trap-Eye, is currently approved in the EU to treat wet AMD and in the US to treat wet AMD and macular edema following CRVO. Commenting on the milestone, Regeneron’s Chief Scientific Officer and President of Regeneron Laboratories, George D. Yancopoulos, M.D., Ph.D., stated that, “we are pleased with the positive recommendation by the CHMP, we hope that we can soon offer patients with visual impairment due to Macular Edema following CRVO, and their treating physicians a new option to address this disease.”